304 related articles for article (PubMed ID: 35390189)
1. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
[TBL] [Abstract][Full Text] [Related]
2. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
Schrezenmeier H; Röth A; Araten DJ; Kanakura Y; Larratt L; Shammo JM; Wilson A; Shayan G; Maciejewski JP
Ann Hematol; 2020 Jul; 99(7):1505-1514. PubMed ID: 32390114
[TBL] [Abstract][Full Text] [Related]
3. Long-term effectiveness of eculizumab: Data from the International PNH Registry.
Terriou L; Lee JW; Forsyth C; Griffin M; Szer J; Röth A; Gustovic P; Metzger J; Patel AS; Patriquin CJ
Eur J Haematol; 2023 Nov; 111(5):796-804. PubMed ID: 37712908
[TBL] [Abstract][Full Text] [Related]
4. Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH Registry.
Dingli D; Maciejewski JP; Larratt L; Go RS; Höchsmann B; Zu K; Gustovic P; Kulagin AD
Ann Hematol; 2023 Jul; 102(7):1637-1644. PubMed ID: 37199789
[TBL] [Abstract][Full Text] [Related]
5. Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry.
Almeida AM; Bedrosian C; Cole A; Muus P; Schrezenmeier H; Szer J; Rosse WF
Intern Med J; 2017 Sep; 47(9):1026-1034. PubMed ID: 28608499
[TBL] [Abstract][Full Text] [Related]
6. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International Paroxysmal Nocturnal Hemoglobinuria Registry.
Röth A; Araten DJ; Larratt L; Kulasekararaj AG; Maciejewski JP; Wilson A; Gustovic P; Kanakura Y
Eur J Haematol; 2020 Nov; 105(5):561-570. PubMed ID: 32640047
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria.
Martí-Carvajal AJ; Anand V; Cardona AF; Solà I
Cochrane Database Syst Rev; 2014 Oct; (10):CD010340. PubMed ID: 25356860
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 Study of Subcutaneous Versus Intravenous Ravulizumab in Eculizumab-Experienced Adult Patients with PNH: Primary Analysis and 1-Year Follow-Up.
Yenerel MN; Sicre de Fontbrune F; Piatek C; Sahin F; Füreder W; Ortiz S; Ogawa M; Ozol-Godfrey A; Sierra JR; Szer J
Adv Ther; 2023 Jan; 40(1):211-232. PubMed ID: 36272026
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in a real-world setting.
Versmold K; Alashkar F; Raiser C; Ofori-Asenso R; Xu T; Liu Y; Katz P; Shang A; Röth A
Eur J Haematol; 2023 Jul; 111(1):84-95. PubMed ID: 36971028
[TBL] [Abstract][Full Text] [Related]
11. Concomitant Immunosuppressive Therapy and Eculizumab Use in Patients with Paroxysmal Nocturnal Hemoglobinuria: An International PNH Registry Analysis.
Hill A; de Latour RP; Kulasekararaj AG; Griffin M; Brodsky RA; Maciejewski JP; Marantz JL; Gustovic P; Schrezenmeier H
Acta Haematol; 2023; 146(1):1-13. PubMed ID: 36108594
[TBL] [Abstract][Full Text] [Related]
12. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.
Jang JH; Kim JS; Yoon SS; Lee JH; Kim YK; Jo DY; Chung J; Sohn SK; Lee JW
J Korean Med Sci; 2016 Feb; 31(2):214-21. PubMed ID: 26839475
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea.
Kim JS; Jang JH; Jo DY; Ahn SY; Yoon SS; Lee JH; Kim SH; Choi CW; Shin HJ; Kim MK; Lee JH; Mun YC; Kong JH; Hyun B; Nam H; Kim E; Kwak MJ; Won YK; Lee JW
J Korean Med Sci; 2023 Oct; 38(41):e328. PubMed ID: 37873628
[TBL] [Abstract][Full Text] [Related]
14. Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications.
Plessier A; Esposito-Farèse M; Baiges A; Shukla A; Garcia Pagan JC; De Raucourt E; Ollivier-Hourmand I; Cervoni JP; De Ledinghen V; Tazi Z; Nousbaum JB; Bun R; Bureau C; Silvain C; Tournilhac O; Gerfaud-Valentin M; Durand F; Goria O; Tellez L; Albillos A; Gioia S; Riggio O; De Gottardi A; Payance A; Rautou PE; Terriou L; Charbonnier A; Elkrief L; de la Tour RP; Valla DC; Gault N; de Fontbrune FS
Am J Hematol; 2022 Apr; 97(4):431-439. PubMed ID: 35049058
[TBL] [Abstract][Full Text] [Related]
15. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
[TBL] [Abstract][Full Text] [Related]
17. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
18. Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan.
Ueda Y; Obara N; Yonemura Y; Noji H; Masuko M; Seki Y; Wada K; Matsuda T; Akiyama H; Ikezoe T; Chiba S; Kanda Y; Kawaguchi T; Shichishima T; Nakakuma H; Okamoto S; Nishimura JI; Kanakura Y; Ninomiya H
Int J Hematol; 2018 Jun; 107(6):656-665. PubMed ID: 29383624
[TBL] [Abstract][Full Text] [Related]
19. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
Nishimura JI
Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
[TBL] [Abstract][Full Text] [Related]
20. One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab.
Kulasekararaj AG; Hill A; Langemeijer S; Wells R; González Fernández FA; Gaya A; Ojeda Gutierrez E; Piatek CI; Mitchell L; Usuki K; Bosi A; Brodsky RA; Ogawa M; Yu J; Ortiz S; Röth A; Lee JW; Peffault de Latour R
Eur J Haematol; 2021 Mar; 106(3):389-397. PubMed ID: 33301613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
